Wellington Management Group
FDMT icon

Wellington Management Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Wellington Management Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.71M Buy
128,464
+19,592
+18% +$191K ﹤0.01% 1662
2026
Q1 		$1.01M Sell
108,872
-21,380
-16% -$186K ﹤0.01% 1672
2025
Q4 		$977K Sell
130,252
-5,218
-4% -$52.9K ﹤0.01% 1720
2025
Q3 		$1.18M Buy
+135,470
New +$810K ﹤0.01% 1743
2025
Q2 		– Sell
-247,471
Closed -$799K – 1981
2025
Q1 		$799K Buy
247,471
+70,192
+40% +$331K ﹤0.01% 1753
2024
Q4 		$987K Buy
177,279
+11,089
+7% +$87K ﹤0.01% 1721
2024
Q3 		$1.8M Sell
166,190
-13,254
-7% -$220K ﹤0.01% 1567
2024
Q2 		$3.77M Buy
179,444
+9,796
+6% +$246K ﹤0.01% 1382
2024
Q1 		$5.4M Sell
169,648
-10,827
-6% -$276K ﹤0.01% 1308
2023
Q4 		$3.66M Buy
180,475
+7,753
+4% +$102K ﹤0.01% 1373
2023
Q3 		$2.2M Buy
172,722
+3,638
+2% +$60.8K ﹤0.01% 1456
2023
Q2 		$3.06M Sell
169,084
-6,432
-4% -$118K ﹤0.01% 1394
2023
Q1 		$3.02M Sell
175,516
-85,188
-33% -$1.66M ﹤0.01% 1402
2022
Q4 		$5.79M Sell
260,704
-5,188
-2% -$80.1K ﹤0.01% 1234
2022
Q3 		$2.14M Buy
265,892
+143,508
+117% +$1.3M ﹤0.01% 1515
2022
Q2 		$855K Hold
122,384
– – ﹤0.01% 1705
2022
Q1 		$1.85M Sell
122,384
-139,563
-53% -$2.19M ﹤0.01% 1624
2021
Q4 		$5.75M Buy
+261,947
New +$6.42M ﹤0.01% 1428
2021
Q2 		– Sell
-90,251
Closed -$3.91M – 2171
2021
Q1 		$3.91M Sell
90,251
-118,928
-57% -$5.27M ﹤0.01% 1479
2020
Q4 		$8.67M Buy
+209,179
New +$8.64M ﹤0.01% 1217

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Wellington Management Group's FDMT Position: Q2 2026 in Review

Wellington Management Group increased its 4D Molecular Therapeutics (FDMT) stake by 18% in Q2 2026, buying an estimated $191K and bringing the position to 128,464 shares worth $1.71M. The position accounts for ﹤0.01% of the portfolio, ranked #1662.

Wellington Management Group first reported a position in FDMT in Q4 2020 and has held it in 20 quarters since. The position peaked at $8.67M in Q4 2020. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Wellington Management Group held 128,464 shares of 4D Molecular Therapeutics worth $1.71M as of Q2 2026.
  • Wellington Management Group bought 19,592 4D Molecular Therapeutics shares in Q2 2026, an estimated $191K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1662 holding.
  • Wellington Management Group first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Wellington Management Group's 4D Molecular Therapeutics position peaked at $8.67M in Q4 2020.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.